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Abstract  28 
Objective:  29 
Patient-reported outcome measures (PROMs) provide a way to measure the impact of a 30 
GLVHDVHDQGLWVDVVRFLDWHGWUHDWPHQWVRQWKHTXDOLW\RIOLIHIURPWKHSDWLHQWV¶SHUVSHFWLYH7KH31 
aim of this review was to identify PROMs that have been developed and/or validated in 32 
patients with carotid artery stenosis (CAS) undergoing revascularisation and to assess their 33 
psychometric properties and examine suitability for research and clinical use. 34 
Methods:  35 
Eight electronic databases including MEDLINE and CINAHL were searched using a two-36 
stage search approach to identify studies reporting the development and/or validation of 37 
relevant PROMs in patients with CAS undergoing revascularisation. Supplementary citation 38 
searching and hand-searching reference lists of included studies were also undertaken. The 39 
COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) 40 
and Oxford criteria were used to assess the methodological quality of the included studies and 41 
the psychometric properties of the PROMs were evaluated using established assessment 42 
criteria. 43 
Results:  44 
Five studies reporting on six PROMs were included: 36-Item Short Form Health Survey (SF-45 
36), Euro-QoL-5-Dimension Scale (EQ-5D), Hospital Anxiety and Depression Scale 46 
(HADS), Dizziness Handicap Inventory (DHI), Quality of life for carotid artery disease scale 47 
and a disease-specific PROM for CAS. The rigour of the psychometric assessment of the 48 
PROMs was variable with most only attempting to assess a single psychometric criterion. No 49 
study reported evidence on construct validity and test-retest reliability. Evidence for 50 
acceptability for the use of SF-36, EQ-5D and the disease-specific PROM were rated good in 51 
most studies. Only one study reported a Cronbach alpha score >0.70 as evidence of internal 52 
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consistency. Overall, the psychometric evaluation of all included PROMs was rated as poor 53 
within the CAS population undergoing revascularisation. 54 
Conclusions:  55 
This review highlighted a lack of evidence in validated PROMs used for patients undergoing 56 
carotid artery revascularisation. As a result, the development and validation of a new PROM 57 
for this patient population is warranted in order to provide data which can supplement 58 
traditional clinical outcomes (stroke<30 days post-procedural, myocardial infarction and 59 
death) and capture changes in health status and quality of life to help inform treatment 60 
decisions. 61 
 62 
Keywords: Carotid artery revascularisation; Patient-Reported Outcome Measures; PROMs; 63 
Quality of life; Vascular surgery; Psychometric.  64 
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1. Introduction 65 
Thromboembolism from carotid artery stenosis (CAS) is a major cause of stroke, accounting 66 
for one in five cases of all strokes.1 Patients with CAS can remain asymptomatic until the 67 
carotid arteries are severely narrowed or blocked and in some cases transient ischaemic attack  68 
or stroke is the first sign of the disease. Patients with severely narrowed or blocked arteries 69 
may undergo a surgical procedure to open the arteries and to prevent stroke and its 70 
complications from occurring, namely death or decrease in quality of life (QoL). 71 
 72 
Patient reported outcome measures (PROMs) are questionnaires completed by the patient in 73 
relation to their health and daily functioning.  This provides a way of measuring the impact of 74 
a disease and its associated treatments on the health and QoL IURPWKHSDWLHQWV¶SHUVSHFWLYH.2 75 
PROMs can be categorised as generic, disease-specific or dimensional specific (measure the 76 
effect of an intervention on a specific concept e.g. anxiety). Generic PROMs can be used in a 77 
variety of conditions and allows comparison across different patient groups. In contrast, 78 
disease-specific PROMs are specific to treatments and symptoms associated with a particular 79 
disease or condition. Both generic and disease-specific PROMs can be preference-based 80 
PROMs and can be used to estimate preference weights for calculating quality-adjusted life-81 
years, from which an economic value of interventions can be assessed.3;4 82 
 83 
The United States Food and Drug Administration (FDA) recommends the use of both generic 84 
and disease-specific measures in clinical trials5 and in the United Kingdom the National 85 
Institute for Health and Care Excellence (NICE) use PROMs data to facilitate health 86 
technology assessments.6 Since 2009 the NHS has made it a requirement to collect PROM 87 
data from patients before and after surgery in four surgical conditions: hip replacement, knee 88 
replacement, varicose vein treatment and groin hernia repair. Currently, PROMs are not 89 
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routinely used in carotid artery revascularisation. The addition of validated PROMs to the 90 
hard clinical outcomes (i.e. stroke < 30 days post-procedural, myocardial infarction and 91 
death) in patients undergoing carotid artery revascularisation, can provide information about 92 
the quality of care and the impact of treatment on a patient¶s QoL including wound 93 
complications, cranial nerve damage, drug side effects and anxiety associated with the 94 
condition and treatments.7 It is important to use PROMs that have followed best practice in 95 
terms of their development and evaluation to ensure the PROMs are µDSSURSULDWHDQG96 
comprehensive relative to its LQWHQGHGPHDVXUHPHQWFRQFHSWSRSXODWLRQDQGXVH¶.2 97 
  98 
The aim of this review was to identify studies reporting on the development and/or validation 99 
of PROMs for use in  patients with CAS undergoing revascularisation, critically appraise the 100 
psychometric properties of the PROMs, and examine its suitability for clinical and research 101 
use. This review forms part of a larger study funded by the NIHR examining the re-102 
configuration of vascular services in the UK and identify targets for future research.  103 
 104 
2. Methods 105 
This systematic review was reported in accordance with the general principles recommended 106 
in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 107 
statement.8 A protocol was developed and registered on the PROSPERO international 108 
prospective register of systematic reviews 109 
(http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42015023877). 110 
 111 
2.1 Data sources and searches 112 
Systematic searches were undertaken in eight electronic databases and research registers 113 
including MEDLINE, MEDLINE in Process, EMBASE, the Cochrane Library, CINAHL, 114 
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PROQOLID, PsychINFO and Web of Science. A two-stage search approach was used. The 115 
first stage combined known generic and condition-specific terms for PROMs and CAS. The 116 
studies were retrieved and examined for additional PROM terms used in CAS. Stage 2 117 
incorporated PROM terms identified in stage 1 with a preliminary search strategy and a 118 
methodological search filter for finding studies on measurement properties.9 Databases were 119 
searched from inception up to February 2015 (for stage 1) and up to May 2015 (for stage 2). 120 
Both searches were updated in February 2017.  No language or date restrictions were applied.  121 
Searches were supplemented by hand-searching the reference lists of relevant reviews and 122 
included studies, citation searching DQGFRQWDFWZLWKH[SHUWVLQWKH¿HOGDetails of the search 123 
strategies are provided in Supplementary Appendix 1. 124 
 125 
2.2 Study selection 126 
All identified titles were examined for inclusion and any citations that clearly did not meet 127 
the inclusion criteria were excluded (e.g. non-human, unrelated to CAS). All abstracts and 128 
full text articles were then examined by at least two reviewers. Any disagreements in the 129 
selection process were resolved by discussion, with involvement of a third reviewer when 130 
necessary. A summary of the inclusion and exclusion criteria is presented in Table I. 131 
  132 
Table I: Study Selection Criteria 133 
 Inclusion criteria Exclusion criteria 
Population A defined population of participants with a 
confirmed diagnosis of CAS (using 
ultrasonography, computed tomography, 
magnetic resonance imaging, or 
Patients not diagnosed with CAS 
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conventional angiography) who need, have 
had, or are undergoing revascularisation.  
 
Intervention Any  surgical treatment indicated for CAS 
e.g. carotid endarterectomy, carotid artery 
stenting and angioplasty 
Non-surgical interventions for CAS 
Outcomes PROMs  (including generic, disease-
specific, preference-based, functional and 
symptoms) used to assess quality of life in 
patients with CAS undergoing 
revascularisation 
Outcome measures of patient 
satisfaction or experience in the 
relevant population  
PROMs from Proxy 
Study design Any   
Publication 
type 
Published or unpublished full-text peer 
reviewed journal articles including 
structured abstracts with all relevant 
information  
Reviews, Editorial and Opinion 
pieces 
 
Language English Non-English 
CAS, carotid artery stenosis; PROMs, Patient reported outcome measures; 
 134 
2.3 Data abstraction  135 
Data relating to study design, patient characteristics, type of surgical treatment, type of 136 
PROM used, methods and outcomes were extracted by one reviewer into a standardised data 137 
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extraction form, and independently checked for accuracy by a second. Any discrepancies 138 
were resolved by discussion, with involvement of a third reviewer, if required.  139 
 140 
2.4 Psychometric evaluation  141 
The methodological quality and the psychometric properties of the included PROMs were 142 
assessed by two independent reviewers. Any disagreements were resolved by discussion and 143 
when needed with the involvement of a third reviewer. Criteria used to appraise the PROMs 144 
(see Table II) were adapted from published recommendations.10-16 These criteria have been 145 
successfully applied  previously17;18 and are consistent with the FDA guidance.2 The 146 
instruments were examined for their reliability (the degree to which measures are 147 
reproducible and consistent over time in patients with a stable condition); validity (the degree 148 
to which the instrument measures what it is supposed to measure); responsiveness (the degree 149 
to which the instrument detects meaningful change over time if a change truly exists) and 150 
acceptability (the degree to which the instrument is acceptable to the patients). As no gold 151 
standard exists for QoL, criterion validity was not assessed.  152 
 153 
Table II: Appraisal criteria for assessing the psychometric properties of patient-154 
reported outcome measures  155 
Domain Sub-domain Criteria 
Reliability Test re-test  
 
The intra-class correlation/ weighted kappa score 
VKRXOGEHIRUJURXSFRPSDULVRQVDQGLI
scores are going to be used for decisions about an 
individual based on their score.10  
The mean difference (paired t test or Wilcoxon signed-
10 
 
rank test) between time point 1 (T1) and time point 2 
(T2) and the 95% CI should also be reported. 
 Internal 
consistency 
$&URQEDFK¶V DOSKDVFRUHRILVFRQVLGHUHGJRRG
DQGLWVKRXOGQRWH[FHHGIRUJURXSFRPSDULVRQV
as this is taken to indicate that items in the scale could 
EHUHGXQGDQW,WHPWRWDOFRUUHODWLRQVVKRXOGEH13  
Validity Content validity 
 
This is assessed qualitatively during the development 
of an instrument. To achieve good content validity, 
there must be evidence that the instrument has been 
developed by consulting patients, experts as well as 
undertaking a literature review.  
Patients should be involved in the development stage 
and item generation. The opinion of patient 
representatives should be sought on the constructed 
scale.10;12;13 
 Construct 
validity 
A correlation co-HIILFLHQWRILVWDNHQDVVWURQJ
evidence of construct validity. Authors should make 
specific directional hypotheses and estimate the 
strength of correlation before testing.10;13;14  
Responsiveness Responsiveness 
 
There are a number of methods to measure this 
including t-tests, effect size, standardised response 
PHDQVRUUHVSRQVLYHQHVVVWDWLVWLFV*X\DWWV¶
responsiveness index.16 There should be statistically 
significant changes in score of an expected 
11 
 
 156 
3. Results 157 
A total of 1,670 records were identified, of which 126 full-text articles were considered 158 
eligible for inclusion.  Following detailed examination, five studies (reporting on the 159 
development and/or validation of six PROMs) were included in this review. All the included 160 
studies reported the validation or development of PROMs in patients with symptomatic 161 
and/or asymptomatic CAS undergoing surgical treatment. The majority of the excluded 162 
studies did not present data evaluating the measurement properties of PROMs and only 163 
reported the use of PROMs in patients with CAS undergoing revascularisation. A summary 164 
of the process for identifying and selecting the relevant literature is presented in Figure 1. 165 
 166 
  167 
 168 
 169 
 170 
 171 
 172 
 173 
 174 
magnitude.15  
Acceptability Floor-ceiling 
effects  
A floor or celling effect is considered if 15% of 
respondents are achieving the lowest or the highest 
score on the instrument.14 
 Acceptability  Acceptability was measured by the completeness of the 
data supplied. 80% or more of the data should be 
complete.12 
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Figure 1: Study flow chart (adapted) of study selection 175 
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 208 
Citations identified through 
database searching  
(n = 1303) 
Additional citations identified 
through other sources  
(n = 367) 
Citations screened by title  
(n = 1670) 
Citations screened by 
abstract  
(n = 688) 
Citations excluded by title  
(n = 982) 
Full-text citations 
assessed for eligibility  
(n = 126) Full-text articles excluded  
(n = 121) 
x No data on evaluation of PROMs 
(n = 89) 
x No useable outcome data (n = 24) 
x Non-CAS population (n = 6) 
x Non-English language publication 
(n = 2) 
 
Citations excluded by 
abstract  
(n = 562) 
Studies included in synthesis  
(n =5) 
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3.1 Study characteristics 209 
Table III presents the study characteristics of the five included studies. All the included 210 
studies used PROMs to assess the health related quality of life (HRQoL) or functional status 211 
of patients undergoing revascularisation and reported aspects of the methodological details of 212 
the PROMs development and/or validation. The studies were prospective in design and were 213 
undertaken in the USA,19 Germany,20 USA/ Canada,21 Taiwan22 and Latvia.23 The studies 214 
were published between 201019 and 2015,23 and the majority of the studies were of a small to 215 
moderate size with the number of participants ranging from 6122 to 2502.21 Adults of either 216 
sex were recruited with the proportion of men ranging between 55%23 to 84%22 and the mean 217 
age range between 69 years21 and 73 years.22 218 
 219 
7KHSDWLHQWV¶FOLQLFDOGLagnosis varied across studies: four studies19-22 included patients with 220 
both symptomatic and asymptomatic carotid artery stenosis, whilst one study, Ivanova et al23 221 
only included asymptomatic patients. The types of surgical treatment reported for carotid 222 
revascularisation included carotid endarterectomy (CEA),20;23 carotid artery stenting (CS)22 223 
and in two studies19;21 both CS and CEA were used.   224 
 225 
Table III: Study and patient characteristics of included studies reporting validation of 226 
PROMs in patients 227 
 228 
 229 
 230 
Author, 
year 
Country Diagnosis 
(Sample size) 
 
Age, 
years 
(mean 
±SD) 
Gender 
n/N (% 
males)  
Reported 
PROM(s) 
Timing of 
PROM(s) 
assessment  
Treatment 
14 
 
Stolker 
201019 
USA 
(SAPPHIRE 
Trial) 
High risk 
patients 
symptomatic 
and 
asymptomatic  
(N=310) 
72 (± 8)  211/310 
(68.1) 
EQ-5D 
SF-36 
Disease-
specific 
PROM 
Baseline, 2 
weeks, 1,6 
and 12 
months 
post-surgery 
CEA 
versus CS 
in high risk 
patients  
Attigah 
201120 
Germany  
 
Symptomatic 
and 
asymptomatic 
carotid stenosis 
(N=102) 
Median 
age 
(range): 
70 (42-
86)  
70/102 
(68.6) 
HADS 
EQ-5D 
1 day before 
and 2 days 
post-surgery 
Local 
anaesthetic 
in CEA 
Cohen 
201121 
USA 
&Canada 
(CREST 
Trial) 
Symptomatic 
and 
asymptomatic 
carotid stenosis  
(N=2,502) 
69 
(NR) 
 
1626/250
2 (65) 
SF-36 
Disease-
specific 
PROM 
Baseline, 2 
weeks, 1 
month and 1 
year post-
surgery 
CEA 
versus CS  
Hsu 
201422 
Taiwan Symptomatic 
and 
asymptomatic 
carotid stenosis 
(N=61)  
73.3 (± 
10.5) 
51/61 
(83.6) 
SF-36 
DHI 
1 week 
before, 1 
and 6 
months 
post-surgery 
CS 
15 
 
 231 
 232 
3.2 PROMs data and psychometric evaluation  233 
Five studies reported data relating to the psychometric evaluation of PROMs in patients 234 
undergoing carotid revascularisation.  Of these, two were generic PROMs: 36-item Short 235 
Form Health Survey (SF-36)19;21;22 and Euro-QoL 5 Dimension Scale (EQ-5D).19;20 Two were 236 
dimension-specific PROMs: Hospital Anxiety & Depression scale (HADS)20 - a mental 237 
health specific PROM and Dizziness Handicap Inventory (DHI)22. Two were condition-238 
specific PROMs: Quality of life for carotid artery disease scale designed by Ivanova et al23 239 
and a disease-specific PROM for CAS19 which was designed for use in the SAPPHIRE trial 240 
(Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy)19 and 241 
was further adapted and used in the CREST study (Carotid Revascularization Endarterectomy 242 
versus Stenting Trial).21 243 
 244 
Ivanova 
201523 
Latvia Asymptomatic 
carotid  
artery stenosis 
(N=120) 
Median 
age 
(range): 
69.3 
(42-84)  
66/120 
(55) 
Quality of 
life for 
carotid 
artery 
disease 
1,3,6,9,12 
months 
before entry 
and 4 
months 
until total of 
24 months 
CEA  
 CS, carotid artery stenting; CEA, carotid endarterectomy; CREST, Carotid Revascularisation 
Endarterectomy Versus Stenting Trial; DHI, Dizziness Handicap Impact; SAPPHIRE, Stenting and 
Angioplasty with Protection in Patients at High Risk for Endarterectomy; PROMs, patient reported 
outcome measure; SD, standard deviation; NR, not reported 
16 
 
The timings of administering the PROMs were different between the five studies. The 245 
shortest post intervention follow-up was two days and the longest was 24 months. The rigour 246 
of the psychometric assessment of the PROMs was variable, with most only attempting to 247 
assess a single psychometric criterion. The evaluation was generally poor across all the 248 
included studies in this review. The results of the psychometric evaluation are presented in 249 
Table IV. In brief, the quality of each psychometric criterion was based on: 1) using the 250 
appropriate statistical test for a specific criterion and 2) the results of the test fulfilled the 251 
criteria mentioned in the methods section and Table II. Each criterion was evaluated 252 
independently and objectively by two independent reviewers.    253 
 254 
Table IV: Summary of the psychometric properties of patient-reported outcome 255 
measures  256 
  PROM Internal 
consistency 
Test re-test 
Reliability 
Content 
validity 
Construct 
validity 
Responsiv-
eness 
Floor/ 
ceiling 
Acceptability 
SF-36  
Cohen  
201121  
0 0 0 0 +/- 0 + 
Stolker 
201019 
0 0 - 0 +/- 0 + 
Hsu 
201422 
? 0 0 0 0 0 0 
EQ-5D  
Stolker 
201019 
0 0 - 0 +/- 0 + 
17 
 
Attigah 
201120 
0 0 0 0 ? 0 0 
Disease-Specific PROM 
Cohen 
201121 
0 0 - 0 ? 0 + 
Stolker 
201119 
0 0 - 0 ? 0 + 
Quality of Life for Carotid Artery Disease 
Ivanova 
201523 
0 0 +/- 0 - - 0 
DHI 
Hsu 
201422 
0 0 0 0 ? 0 0 
HADS 
Attigah 
201120 
0 0 0 0 ? 0 0 
DHI, Dizziness Handicap Impact; EQ-5D, EuroQol 5 dimensions; HADS, hospital anxiety and 
depression scale; PROMs, patient reported outcome measures; SF-36, 36-item Short Form Medical 
Outcomes Study 
Psychometric and operational criteria:  
0 Not reported (no evaluation completed) 
- Evidence not in favour 
-/+ Weak evidence 
+ Evidence in favour 
? Methodology questionable  
18 
 
The SAPPHIRE trial19 included high-risk patients with symptomatic carotid stenosis of >50% 257 
and patients with asymptomatic CAS with >80% stenosis.  Patients were randomised to either 258 
the CS arm (159 patients) or the CEA arm (151 patients). HRQoL was assessed at baseline, 259 
two weeks and one, six and 12 months using SF-36, EQ-5D and a disease-specific PROM 260 
with six questions asking about difficulty with walking, eating/swallowing, driving, 261 
headache, neck pain and leg pain. The study did not report any qualitative evidence to 262 
support the content validity of the disease-specific PROM. Only four- subscales of the SF-36 263 
were used (physical function, role limitations, pain, vitality), the authors justified this 264 
decision that only these four dimensions were sensitive to differences between CS versus 265 
CEA and provided no further evidence. However, data on three of these subscales were not 266 
sensitive at all and did not show any statistically significant change from baseline, only the 267 
physical scale of SF-36 showed some responsiveness at two weeks. The disease-specific 268 
PROM in this study did not undergo further psychometric analysis to assess its 269 
responsiveness. The strongest feature of PROMs used in this study was acceptability with 270 
data completeness being above 80%. 271 
 272 
The CREST trial21 included data from 2,502 patients with symptomatic and asymptomatic 273 
CAS. 1,262 patients were assigned to CS and 1,240 to the CEA arm of the trial. HRQoL was 274 
assessed at baseline, two weeks, one month and one year post intervention using SF-36 and 275 
an adapted version of the disease-specific PROM from the SAPPHIRE trial.19 The disease-276 
specific PROM included eight questions (including difficulty in walking, difficulty in 277 
swallowing/eating, driving, neck pain, headaches, leg pain, level of overall pain and the 278 
number of times pain medications were needed). No qualitative evidence for content validity, 279 
internal consistency and reliability of either instrument was provided. However, both 280 
instruments showed good acceptability with data completion rates of 85 to 90%. The SF-36 281 
19 
 
scores improved across five out of eight dimensions of health (P value < 0.01) at two weeks 282 
for patients undergoing CS versus CEA.  283 
 284 
Attigh et al20 assessed HRQoL in 102 patients undergoing CEA under local anaesthetic. The 285 
SF-36 and HADS were used to assess HRQoL. Evidence on validity, reliability, acceptability 286 
and consistency were not reported for either PROM. The psychometric evaluation only 287 
concentrated on responsiveness using univariate comparisons and multivariate analysis, 288 
neither of which was suitable for assessing the responsiveness of the PROMs.  289 
The CAS specific PROM was developed by Ivanova et al.23 The initial version was based on 290 
generic and neurovascular specific HRQoL questionnaires. This was reviewed by patients 291 
with CAS and clinicians. The final draft included 17 domains each with four choices. The 292 
PROM was assessed in 120 patients with asymptomatic CAS, one to three days before CEA 293 
and six to seven months after that. The authors reported improved physical, functional, 294 
psychological and social function but these were not statistically significant. Furthermore, 295 
many domains had floor/ceiling effects of more than 28.5% raising questions regarding the 296 
relevance of some of the questions included in this PROM.  297 
 298 
Hsu et al22 assessed the effect of CS on HRQoL in patients with CAS suffering with 299 
dizziness. Of the 178 patients who underwent CS, only 61 complained of dizziness. HRQoL 300 
was assessed using SF-36 and DHI. The SF-36 showed evidence of internal consistency 301 
(CroQEDFK¶V alpha score >0.70) but the statistical assessment of responsiveness was based on 302 
non-parametric measures and no evidence was presented regarding the completeness of the 303 
data for each of the domains.  304 
 305 
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4. Discussion 306 
This review identified six PROMs in five studies19-23 that reported details on the development 307 
and/or validation of PROMs for use in patients with CAS undergoing revascularisation. The 308 
quality of the instruments was variable with respect to their development and psychometric 309 
properties. None of the identified PROMs had undergone rigorous psychometric validation in 310 
patients undergoing carotid artery revascularisation.  Validation of basic psychometric 311 
criteria such as construct validity and test-retest reliability had not been undertaken. Only one 312 
study, Hsu et al22 attempted to assess the internal consistency of SF-36 although the 313 
methodology they used was questionable. Based on the findings of our review it is not 314 
possible to recommend a PROM for use in patients with CAS undergoing revascularisation.  315 
 316 
The strength of the review lies on our comprehensive and extensive search strategy which 317 
was used to identify relevant studies. In addition, to minimise bias two reviewers undertook 318 
the screening, data coding, data extraction and psychometric analysis of all the studies, and 319 
the review covered all types of study designs. The methodological quality assessment criteria 320 
were developed from published studies as per FDA PROMs development guidance.2 321 
However, there are a number of limitations to our review which warrant caution to its 322 
application. The patient population included in this systematic review were heterogeneous in 323 
terms of the type of CAS, the stage of disease, and treatment pathway. For example, the 324 
Quality of life for carotid artery disease scale, reported by Ivanova et al23 was developed in a 325 
Latvian population and the PROMs reported  in Hsu et al (DHI and SF-36)22 underwent 326 
validation in a Chinese population. As a result, the application of the findings from these 327 
studies to English speaking people is uncertain due to language validation and cross-cultural 328 
adaptation of PROMs.11 It is important to note that these limitations are principally sourced in 329 
the evidence base, rather than the methods used to interrogate and evaluate it.    330 
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 331 
It is recommended that PROMs data is collected and evaluated as part of randomised 332 
controlled trials (RCTs) and service analysis.3;24-26 Evidence from this review shows that 333 
most PROMs used in previous carotid trials lacked validation.  Another tool occasionally 334 
used to assess functional HRQOL outcomes following CS or CEA in clinical trials is the 335 
modified Rankin scale27 (a functional assessment scale for assessing handicap in stroke 336 
patients).28 However, the Rankin score was not included in this review as it does not capture a 337 
SDWLHQW¶VVXEMHFWLYHSHUFHSWLRQRIWKHLU4R/DQGWKXVFDQQRWEHFRQVLGHUHGWREHa true 338 
PROM.29 The benefits of supplementing clinical outcome data with a well-developed, valid, 339 
consistent, reliable and responsive instrument could help provide more targeted data on 340 
aspects such as how patients feel after specific interventions, treatment efficacy, and 341 
identification of patients most likely to benefit from the procedure. Particularly since the 342 
intervention procedure is frequently done in patients who might be asymptomatic. Hence, 343 
having a universal accepted PROM measure for assessing QoL in patients undergoing carotid 344 
revascularisation will be valuable to the patients, clinicians and decision makers to guide 345 
them in providing an efficient and cost-effective treatment plan. 346 
 347 
Some of the issues noted in this review maybe addressed by either developing a disease-348 
specific PROM or developing a set of questions specific to CAS which can be added to 349 
complement a generic PROM (e.g. SF-36 or EQ-5D) as recommended by regulating bodies.6 350 
However, when developing a PROM questionnaire it is important to use qualitative methods 351 
involving patients and clinicians and insure the questionnaire captures both the breadth of the 352 
patient experience and the instrument to be reliable, valid, responsive and acceptable to 353 
patients.  The questionnaire should be easy to administer and attention should be given to its 354 
format, setting and time required for completion. In addition, research exploring how to 355 
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integrate PROMs into the patient pathway needs to be undertaken, including when and at 356 
what time-points should the PROM be administered.  357 
 358 
5. Conclusion 359 
This review highlights a lack of evidence for valid, reliable, responsive and acceptable 360 
PROMs for use in patients undergoing carotid artery revascularisation. As a result, the 361 
development and validation of a new PROM for this patient population is warranted in order 362 
to provide data which can supplement traditional clinical outcomes (stroke<30 days post-363 
procedural, myocardial infarction and death) and capture changes in health status and quality 364 
of life to help inform treatment decisions. 365 
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